Further, in vivo studies of a breast cancer model have shown that a combinatorial treatment involving HIF-1 inhibitors, reducing the VEGF-A and FoxP3 expression, and a DC-based vaccine, gave rise to a strong anti-tumor cytotoxic T cell immune response with an increased IFN-γ production and reduced Treg cell activation32. The gene discussed is VEGFA; the disease is breast carcinoma.